Cover Image
Market Research Report

Eye Infections Treatment Market: By Category (Conjunctivitis, Blepharitis, Keratitis, Others); By Cause of Infection (Bacteria, Viruses, Irritants, Allergies); By Drug Type (Corticosteroids, Others) & By Region (Europe, Others) -Forecast 2019-2024

Published by IndustryARC Product code 421918
Published Content info
Delivery time: 2-3 business days
Price
Back to Top
Eye Infections Treatment Market: By Category (Conjunctivitis, Blepharitis, Keratitis, Others); By Cause of Infection (Bacteria, Viruses, Irritants, Allergies); By Drug Type (Corticosteroids, Others) & By Region (Europe, Others) -Forecast 2019-2024
Published: December 27, 2018 Content info:
Description

Eye Infections are caused due to various viruses, bacteria, parasites, and fungi that can invade the human body. It is more frequent in Afro-Caribbean's, Arabs, and Asian countries having warmer climate. Globally, availability of new and more efficient drugs such as eye drop or eye ointment, change in population demographics, and increasing frequency of blindness amongst the geriatric population are the prime growth drivers of global eye infections treatment market. In addition, increase in adoption of eye infections treatment drugs in emerging economies such as China, India and others owing to growing health awareness and government initiatives, and countries with warm climatic conditions will create new opportunities for global eye infections treatment market. However, higher cost of the research and development, and testing, and stringent government regulations are the key restraints for global eye infections treatment market.

This report identifies the global eye infections treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global eye infections treatment market.

Geographically Asia dominated global eye infections treatment market, and is projected to have fastest growth, owing to rapidly increasing aging population, warm climatic condition and modernizing healthcare infrastructure in this region. Among all the category of eye infection, conjunctivitis has the highest market share in global eye infections treatment market.

This report segments global eye infections treatment market on the basis of category, cause of infection, drug type, end-user, and regional market as follows:

Eye Infections Treatment Market, By Category: Conjunctivitis, Blepharitis, Keratitis, Vitritis, Chorioretinitis and Neuroretinitis

Eye Infections Treatment Market, By Cause of Infection: Bacteria, Viruses, Irritants and Allergies

Eye Infections Treatment Market, By Drug Type: Corticosteroids, Quinolone Antibiotics, Macrolide Antibiotics, Tetracycline Antibiotics, Polyene Antifungals, Aminoglycoside Antibiotic / Polypeptide Antibiotic / Corticosteroid Combinations, Aminoglycoside Antibiotics, Sulfa Antibiotics and Others

This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the eye infections treatment market. Some of the major companies' profiles in detail are as follows:

Roche Holding AG

GlaxoSmithKline Pharmaceuticals Ltd

Valeant Pharmaceuticals International, Inc.

Novartis International AG

Santen Pharmaceutical Co., Ltd.

Table of Contents

Table of Contents

1. Eye Infections Treatment Market - Market Overview

2. Executive Summary

3. Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Eye Infections Treatment Market- Market Forces

  • 4.1. Drivers
    • 4.1.1. Availability of new and more efficient drugs such as eye drop or eye ointment
    • 4.1.2. Change in population demographics
    • 4.1.3. Increasing frequency of blindness amongst the geriatric population
  • 4.2. Restraints
    • 4.2.1. The research and development, and testing having higher cost
    • 4.2.2. Stringent government regulations
  • 4.3. Opportunities
    • 4.3.1. Countries with warm climatic conditions
    • 4.3.2. Increase in adoption of eye infections treatment drugs
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Eye Infections Treatment Market, By Category

  • 5.1. Conjunctivitis
  • 5.2. Blepharitis
  • 5.3. Keratitis
  • 5.4. Vitritis
  • 5.5. Chorioretinitis
  • 5.6. Neuroretinitis

6. Eye Infections Treatment Market, By Cause of Infection

  • 6.1. Bacteria
  • 6.2. Viruses
  • 6.3. Irritants
  • 6.4. Allergies

7. Eye Infections Treatment Market, By Drug Type

  • 7.1. Corticosteroids
  • 7.2. Quinolone Antibiotics
  • 7.3. Macrolide Antibiotics
  • 7.4. Tetracycline Antibiotics
  • 7.5. Polyene Antifungals
  • 7.6. Aminoglycoside Antibiotic / Polypeptide Antibiotic / Corticosteroid Combinations
  • 7.7. Aminoglycoside Antibiotics
  • 7.8. Sulfa Antibiotics
  • 7.9. Others

8. Eye Infections Treatment Market, By Geography

  • 8.1. Europe
    • 8.1.1. Germany
    • 8.1.2. France
    • 8.1.3. Italy
    • 8.1.4. Spain
    • 8.1.5. Russia
    • 8.1.6. U.K.
    • 8.1.7. Rest of Europe
  • 8.2. Asia Pacific
    • 8.2.1. China
    • 8.2.2. India
    • 8.2.3. Japan
    • 8.2.4. South Korea
    • 8.2.5. Rest of Asia-Pacific
  • 8.3. North America
    • 8.3.1. U.S.
    • 8.3.2. Canada
    • 8.3.3. Mexico
  • 8.4. Rest of the World (RoW)
    • 8.4.1. Brazil
    • 8.4.2. Rest of RoW

9. Eye Infections Treatment - Market Entropy

  • 9.1. Expansion
  • 9.2. Technological Developments
  • 9.3. Merger & Acquisitions, and Joint Ventures
  • 9.4. Supply- Contract

10. Company Profiles (Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)

  • 10.1. Roche Holding AG
  • 10.2. GlaxoSmithKline Pharmaceuticals Ltd
  • 10.3. Valeant Pharmaceuticals International, Inc.
  • 10.4. Novartis International AG
  • 10.5. Santen Pharmaceutical Co., Ltd.
  • 10.6. Pfizer Inc.
  • 10.7. Valeant Pharmaceuticals International, Inc.
  • 10.8. Merck & Co.
  • 10.9. Allergan, Plc
  • 10.10. Bayer AG

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

11. Appendix

  • 11.1. Abbreviations
  • 11.2. Sources
  • 11.3. Research Methodology
  • 11.4. Expert Insights
Back to Top